Hypothesis

Co‑administration of a low‑dose UDP‑glucuronosyltransferase (UGT) inhibitor with quercetin phytosome will increase the free quercetin aglycone fraction in plasma above the senolytic IC₅₀ (10‑50 µM) for a sustained period, leading to measurable reductions in senescence‑associated secretory phenotype (SASP) biomarkers and senescent cell burden.

Rationale

Phytosome and LipoMicel formulations boost total quercetin exposure (~20‑fold and 7‑fold AUC improvements, respectively) [1][2] but current human pharmacokinetic data report only total metabolite levels, not the pharmacologically active free aglycone. In vitro senolytic activity requires unconjugated quercetin to bind and inhibit anti‑apoptotic Bcl‑2 family proteins (e.g., Bcl‑xL) that sustain senescent cell survival [3]. Extensive phase‑II metabolism (glucuronidation, sulfation, methylation) rapidly converts absorbed quercetin into hydrophilic conjugates that have markedly lower affinity for these targets, rendering most of the absorbed pool inert for senolysis despite high total AUC.

A transient blockade of UGT enzymes—achievable with a clinically safe dose of probenecid or similar agent—would decrease the rate of quercetin glucuronidation, thereby raising the free‑aglycone fraction and prolonging its presence above the senolytic threshold. This approach directly addresses the disconnect between enhanced total absorption and lack of evidence for functional senolytic activity in humans.

Testable Predictions

1. Plasma free quercetin (measured by LC‑MS/MS after enzymatic deconjugation) will exceed 10 µM for at least 2 h post‑dose when phytosome is given with a UGT inhibitor, whereas phytosome alone will remain below this threshold.
2. The free‑aglycone exposure (AUC₀₋₄ of unconjugated quercetin) will correlate inversely with plasma IL‑6 and IL‑8 levels at 6 h and 24 h post‑dose.
3. Peripheral blood mononuclear cell (PBMC) p16INK4a mRNA expression—a marker of senescent cell burden—will show a significant reduction (≥20 %) 48 h after the combination treatment compared with phytosome alone or placebo.
4. No increase in adverse liver enzymes or bilirubin will be observed at the low inhibitor dose, confirming a favorable safety window.

Proposed Experiment

A randomized, double‑blind, crossover trial in healthy adults (n = 30) will compare three arms: (A) quercetin phytosome 500 mg, (B) quercetin phytosome 500 mg + probenecid 250 mg (low dose), and (C) matched placebo. Blood draws will be taken at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 h. Free quercetin will be quantified after β‑glucuronidase/sulfatase treatment; total quercetin will serve as a comparator. SASP cytokines (IL‑6, IL‑8, MCP‑1) and PBMC p16INK4a expression will be measured in parallel. Statistical analysis will use repeated‑measures ANOVA with post‑hoc Tukey tests; significance set at p < 0.05.

If the combination yields free‑aglycone concentrations that surpass senolytic thresholds and translates into reduced SASP markers and senescent cell signatures, the hypothesis will be supported. Failure to observe these changes despite increased total exposure would falsify the premise that free aglycone limitation is the key barrier, directing focus toward alternative mechanisms (e.g., tissue‑specific delivery or metabolite activity).